Replies to post #183205 on Biotech Values

[oldberkeley]

I genuinely enjoy reading their board because they’re an endless source of self-righteous us-against-them paranoia and self-referential claptrap posing as wisdom. Much of it is truly LOL stuff.

I thought that perhaps they had this market cornered, but now I realize the AMRN board has been coming on strong around the far turn and they’re neck and neck down the stretch.

[DewDiligence]

Cheesy PR from PPHM produces share-price downdraft:

http://finance.yahoo.com/news/phase-ii-clinical-data-presented-123000418.html

Data from this translational sub-study consisting of six patients show that half of the patients evaluated had an increase in tumor fighting immune cells following one cycle of treatment, similar to what has been shown for PS-targeting antibodies in multiple preclinical cancer models.

Few biotech companies would have even considered issuing a PR for this, IMO.